1887

Abstract

The humoral response to hepatitis C virus (HCV) may contribute to controlling infection. We previously isolated human monoclonal antibodies to conformational epitopes on the HCV E2 glycoprotein. Here, we report on their ability to inhibit infection by retroviral pseudoparticles incorporating a panel of full-length E1E2 clones representing the full spectrum of genotypes 1–6. We identified one antibody, CBH-5, that was capable of neutralizing every genotype tested. It also potently inhibited chimeric cell culture-infectious HCV, which had genotype 2b envelope proteins in a genotype 2a (JFH-1) background. Analysis using a panel of alanine-substitution mutants of HCV E2 revealed that the epitope of CBH-5 includes amino acid residues that are required for binding of E2 to CD81, a cellular receptor essential for virus entry. This suggests that CBH-5 inhibits HCV infection by competing directly with CD81 for a binding site on E2.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83386-0
2008-03-01
2019-10-22
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/3/653.html?itemId=/content/journal/jgv/10.1099/vir.0.83386-0&mimeType=html&fmt=ahah

References

  1. Allander, T., Drakenberg, K., Beyene, A., Rosa, D., Abrignani, S., Houghton, M., Widell, A., Grillner, L. & Persson, M. A. ( 2000; ). Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J Gen Virol 81, 2451–2459.
    [Google Scholar]
  2. Anonymous ( 1999; ). Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6, 35–47.[CrossRef]
    [Google Scholar]
  3. Bartosch, B., Bukh, J., Meunier, J. C., Granier, C., Engle, R. E., Blackwelder, W. C., Emerson, S. U., Cosset, F. L. & Purcell, R. H. ( 2003a; ). In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 100, 14199–14204.[CrossRef]
    [Google Scholar]
  4. Bartosch, B., Dubuisson, J. & Cosset, F. L. ( 2003b; ). Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197, 633–642.[CrossRef]
    [Google Scholar]
  5. Bartosch, B., Vitelli, A., Granier, C., Goujon, C., Dubuisson, J., Pascale, S., Scarselli, E., Cortese, R., Nicosia, A. & Cosset, F. L. ( 2003c; ). Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-BI scavenger receptor. J Biol Chem 278, 41624–41630.[CrossRef]
    [Google Scholar]
  6. Bowen, D. G. & Walker, C. M. ( 2005; ). Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436, 946–952.[CrossRef]
    [Google Scholar]
  7. Brown, R. J., Juttla, V. S., Tarr, A. W., Finnis, R., Irving, W. L., Hemsley, S., Flower, D. R., Borrow, P. & Ball, J. K. ( 2005; ). Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection. J Gen Virol 86, 1931–1942.[CrossRef]
    [Google Scholar]
  8. Bugli, F., Mancini, N., Kang, C. Y., Di Campli, C., Grieco, A., Manzin, A., Gabrielli, A., Gasbarrini, A., Fadda, G. & other authors ( 2001; ). Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. J Virol 75, 9986–9990.[CrossRef]
    [Google Scholar]
  9. Bukh, J., Miller, R. H. & Purcell, R. H. ( 1995; ). Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 15, 41–63.[CrossRef]
    [Google Scholar]
  10. Clayton, R. F., Owsianka, A., Aitken, J., Graham, S., Bhella, D. & Patel, A. H. ( 2002; ). Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol 76, 7672–7682.[CrossRef]
    [Google Scholar]
  11. Cocquerel, L., Voisset, C. & Dubuisson, J. ( 2006; ). Hepatitis C virus entry: potential receptors and their biological functions. J Gen Virol 87, 1075–1084.[CrossRef]
    [Google Scholar]
  12. Conrad, M. E. & Lemon, S. M. ( 1987; ). Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin. J Infect Dis 156, 56–63.[CrossRef]
    [Google Scholar]
  13. Drummer, H. E., Boo, I., Maerz, A. L. & Poumbourios, P. ( 2006; ). A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J Virol 80, 7844–7853.[CrossRef]
    [Google Scholar]
  14. Eren, R., Landstein, D., Terkieltaub, D., Nussbaum, O., Zauberman, A., Ben-Porath, J., Gopher, J., Buchnick, R., Kovjazin, R. & other authors ( 2006; ). Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 80, 2654–2664.[CrossRef]
    [Google Scholar]
  15. Farci, P., Alter, H. J., Wong, D. C., Miller, R. H., Govindarajan, S., Engle, R., Shapiro, M. & Purcell, R. H. ( 1994; ). Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 91, 7792–7796.[CrossRef]
    [Google Scholar]
  16. Farci, P., Shimoda, A., Coiana, A., Diaz, G., Peddis, G., Melpolder, J. C., Strazzera, A., Chien, D. Y., Munoz, S. J. & other authors ( 2000; ). The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288, 339–344.[CrossRef]
    [Google Scholar]
  17. Flint, M., Maidens, C., Loomis-Price, L. D., Shotton, C., Dubuisson, J., Monk, P., Higginbottom, A., Levy, S. & McKeating, J. A. ( 1999; ). Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 73, 6235–6244.
    [Google Scholar]
  18. Gale, M., Jr & Foy, E. M. ( 2005; ). Evasion of intracellular host defence by hepatitis C virus. Nature 436, 939–945.[CrossRef]
    [Google Scholar]
  19. Goffard, A., Callens, N., Bartosch, B., Wychowski, C., Cosset, F. L., Montpellier, C. & Dubuisson, J. ( 2005; ). Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol 79, 8400–8409.[CrossRef]
    [Google Scholar]
  20. Habersetzer, F., Fournillier, A., Dubuisson, J., Rosa, D., Abrignani, S., Wychowski, C., Nakano, I., Trepo, C., Desgranges, C. & Inchauspe, G. ( 1998; ). Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. Virology 249, 32–41.[CrossRef]
    [Google Scholar]
  21. Hadlock, K. G., Lanford, R. E., Perkins, S., Rowe, J., Yang, Q., Levy, S., Pileri, P., Abrignani, S. & Foung, S. K. ( 2000; ). Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 74, 10407–10416.[CrossRef]
    [Google Scholar]
  22. Helle, F., Goffard, A., Morel, V., Duverlie, G., McKeating, J., Keck, Z. Y., Foung, S., Penin, F., Dubuisson, J. & Voisset, C. ( 2007; ). The neutralizing activity of anti-HCV antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 81, 8101–8111.[CrossRef]
    [Google Scholar]
  23. Hsu, M., Zhang, J., Flint, M., Logvinoff, C., Cheng-Mayer, C., Rice, C. M. & McKeating, J. A. ( 2003; ). Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 100, 7271–7276.[CrossRef]
    [Google Scholar]
  24. Johansson, D. X., Voisset, C., Tarr, A. W., Aung, M., Ball, J. K., Dubuisson, J. & Persson, M. A. ( 2007; ). Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci U S A 104, 16269–16274.[CrossRef]
    [Google Scholar]
  25. Kapadia, S. B., Barth, H., Baumert, T., McKeating, J. A. & Chisari, F. V. ( 2007; ). Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol 81, 374–383.[CrossRef]
    [Google Scholar]
  26. Keck, Z. Y., Op De Beeck, A., Hadlock, K. G., Xia, J., Li, T. K., Dubuisson, J. & Foung, S. K. ( 2004; ). Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol 78, 9224–9232.[CrossRef]
    [Google Scholar]
  27. Keck, Z. Y., Li, T. K., Xia, J., Bartosch, B., Cosset, F. L., Dubuisson, J. & Foung, S. K. ( 2005; ). Analysis of a highly flexible conformational immunogenic domain A in hepatitis C virus E2. J Virol 79, 13199–13208.[CrossRef]
    [Google Scholar]
  28. Keck, Z. Y., Xia, J., Cai, Z., Li, T. K., Owsianka, A. M., Patel, A. H., Luo, G. & Foung, S. K. ( 2007; ). Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol 81, 1043–1047.[CrossRef]
    [Google Scholar]
  29. Knodell, R. G., Conrad, M. E., Ginsberg, A. L. & Bell, C. J. ( 1976; ). Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis. Lancet 1, 557–561.
    [Google Scholar]
  30. Koutsoudakis, G., Herrmann, E., Kallis, S., Bartenschlager, R. & Pietschmann, T. ( 2007; ). The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J Virol 81, 588–598.[CrossRef]
    [Google Scholar]
  31. Lavillette, D., Morice, Y., Germanidis, G., Donot, P., Soulier, A., Pagkalos, E., Sakellariou, G., Intrator, L., Bartosch, B. & other authors ( 2005a; ). Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 79, 6023–6034.[CrossRef]
    [Google Scholar]
  32. Lavillette, D., Tarr, A. W., Voisset, C., Donot, P., Bartosch, B., Bain, C., Patel, A. H., Dubuisson, J., Ball, J. K. & Cosset, F. L. ( 2005b; ). Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41, 265–274.[CrossRef]
    [Google Scholar]
  33. Lindenbach, B. D., Evans, M. J., Syder, A. J., Wolk, B., Tellinghuisen, T. L., Liu, C. C., Maruyama, T., Hynes, R. O., Burton, D. R. & other authors ( 2005; ). Complete replication of hepatitis C virus in cell culture. Science 309, 623–626.[CrossRef]
    [Google Scholar]
  34. Meylan, E. & Tschopp, J. ( 2006; ). Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell 22, 561–569.[CrossRef]
    [Google Scholar]
  35. Nakabayashi, H., Taketa, K., Miyano, K., Yamane, T. & Sato, J. ( 1982; ). Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42, 3858–3863.
    [Google Scholar]
  36. Op De Beeck, A., Voisset, C., Bartosch, B., Ciczora, Y., Cocquerel, L., Keck, Z., Foung, S., Cosset, F. L. & Dubuisson, J. ( 2004; ). Characterization of functional hepatitis C virus envelope glycoproteins. J Virol 78, 2994–3002.[CrossRef]
    [Google Scholar]
  37. Owsianka, A., Clayton, R. F., Loomis-Price, L. D., McKeating, J. A. & Patel, A. H. ( 2001; ). Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol 82, 1877–1883.
    [Google Scholar]
  38. Owsianka, A., Tarr, A. W., Juttla, V. S., Lavillette, D., Bartosch, B., Cosset, F. L., Ball, J. K. & Patel, A. H. ( 2005; ). Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 79, 11095–11104.[CrossRef]
    [Google Scholar]
  39. Owsianka, A. M., Timms, J. M., Tarr, A. W., Brown, R. J., Hickling, T. P., Szwejk, A., Bienkowska-Szewczyk, K., Thomson, B. J., Patel, A. H. & Ball, J. K. ( 2006; ). Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol 80, 8695–8704.[CrossRef]
    [Google Scholar]
  40. Perotti, M., Mancini, N., Diotti, R. A., Tarr, A. W., Ball, J. K., Owsianka, A., Adair, R., Patel, A. H., Clementi, M. & Burioni, R. ( 2008; ). Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the HCV\E2 protein. J Virol in press
    [Google Scholar]
  41. Pestka, J. M., Zeisel, M. B., Blaser, E., Schurmann, P., Bartosch, B., Cosset, F. L., Patel, A. H., Meisel, H., Baumert, J. & other authors ( 2007; ). Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 104, 6025–6030.[CrossRef]
    [Google Scholar]
  42. Roccasecca, R., Ansuini, H., Vitelli, A., Meola, A., Scarselli, E., Acali, S., Pezzanera, M., Ercole, B. B., McKeating, J. & other authors ( 2003; ). Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol 77, 1856–1867.[CrossRef]
    [Google Scholar]
  43. Rosa, D., Campagnoli, S., Moretto, C., Guenzi, E., Cousens, L., Chin, M., Dong, C., Weiner, A. J., Lau, J. Y. & other authors ( 1996; ). A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A 93, 1759–1763.[CrossRef]
    [Google Scholar]
  44. Sandrin, V., Boulanger, P., Penin, F., Granier, C., Cosset, F. L. & Bartosch, B. ( 2005; ). Assembly of functional hepatitis C virus glycoproteins on infectious pseudoparticles occurs intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins. J Gen Virol 86, 3189–3199.[CrossRef]
    [Google Scholar]
  45. Schofield, D. J., Bartosch, B., Shimizu, Y. K., Allander, T., Alter, H. J., Emerson, S. U., Cosset, F. L. & Purcell, R. H. ( 2005; ). Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology 42, 1055–1062.[CrossRef]
    [Google Scholar]
  46. Shimizu, Y. K., Hijikata, M., Iwamoto, A., Alter, H. J., Purcell, R. H. & Yoshikura, H. ( 1994; ). Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 68, 1494–1500.
    [Google Scholar]
  47. Shoukry, N. H., Cawthon, A. G. & Walker, C. M. ( 2004; ). Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol 58, 391–424.[CrossRef]
    [Google Scholar]
  48. Simmonds, P., Bukh, J., Combet, C., Deleage, G., Enomoto, N., Feinstone, S., Halfon, P., Inchauspe, G., Kuiken, C. & other authors ( 2005; ). Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42, 962–973.[CrossRef]
    [Google Scholar]
  49. Tarr, A. W., Owsianka, A. M., Timms, J. M., McClure, C. P., Brown, R. J., Hickling, T. P., Pietschmann, T., Bartenschlager, R., Patel, A. H. & Ball, J. K. ( 2006; ). Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 43, 592–601.[CrossRef]
    [Google Scholar]
  50. Thimme, R., Lohmann, V. & Weber, F. ( 2006; ). A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res 69, 129–141.[CrossRef]
    [Google Scholar]
  51. Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Krausslich, H. G. & other authors ( 2005; ). Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11, 791–796.[CrossRef]
    [Google Scholar]
  52. Yu, M. Y., Bartosch, B., Zhang, P., Guo, Z. P., Renzi, P. M., Shen, L. M., Granier, C., Feinstone, S. M., Cosset, F. L. & Purcell, R. H. ( 2004; ). Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A 101, 7705–7710.[CrossRef]
    [Google Scholar]
  53. Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D. R., Wieland, S. F., Uprichard, S. L., Wakita, T. & Chisari, F. V. ( 2005; ). Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102, 9294–9299.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83386-0
Loading
/content/journal/jgv/10.1099/vir.0.83386-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error